A Phase 1 interventional study of MT-4129 and Placebo in Healthy, sponsored by Mitsubishi Tanabe Pharma Corporation. Completed at 1 site in Netherlands. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-18.
Sponsored by Mitsubishi Tanabe Pharma Corporation · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to investigate the safety and tolerability of ascending single and multiple oral doses of MT-4129 in healthy subjects.
Mitsubishi Tanabe Pharma Corporation is the lead sponsor of 40 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MT-4129 · Drug: Placebo
Drug: MT-4129 · Drug: Placebo
Safety and Tolerability as measured by incidence and severity of adverse events
Time frame: Up to Day 14
Safety and Tolerability as measured by vital signs
Time frame: Up to Day 14
Safety and Tolerability as measured by ECG
Time frame: Up to Day 14
Safety and Tolerability as measured by clinical laboratory assessments
Time frame: Up to Day 14
Safety and Tolerability as measured by Hormone assessments
Time frame: Up to Day 10
Safety and Tolerability as measured by physical examination
Time frame: Up to Day 14
Maximum observed plasma concentration (Cmax) of MT-4129
Time frame: Up to Day 10
Measured time of maximum observed plasma concentration (tmax) of MT-4129
Time frame: Up to Day 10
Apparent terminal elimination half-life (t1/2) of MT-4129
Time frame: Up to Day 10
AUC from time zero to 24 hours post-dose (AUC0-24) of MT-4129
Time frame: Up to Day 8
AUC from time zero to 48 hours post-dose (AUC0-48) of MT-4129
Time frame: Up to Day 9
AUC from time zero to 72 hours post-dose (AUC0-72) of MT-4129
Time frame: Up to Day 10
AUC from time zero to infinity (AUC0-∞) of MT-4129
Time frame: Up to Day 10
AUC from time zero to the last measurable concentration (AUC0-last) of MT-4129
Time frame: Up to Day 10
AUC over the dosing interval (AUC0-t) of MT-4129
Time frame: Up to Day 10
Terminal elimination rate constant (Kel) of MT-4129
Time frame: Up to Day 10
Mean residence time (MRT) of MT-4129
Time frame: Up to Day 10
Apparent volume of distribution during terminal phase after oral administration (Vz/F) of MT-4129
Time frame: Up to Day 10
Apparent volume of distribution at steady state (Vss/F) of MT-4129
Time frame: Up to Day 10
Apparent oral clearance (CL/F) of MT-4129
Time frame: Up to Day 10
Urinary excreted amount of test compound (Ae) of MT-4129
Time frame: Up to Day 10
Urinary excreted amount of test compound expressed as a percentage of the dose administered (Ae%) of MT-4129
Time frame: Up to Day 10
Renal clearance (CLR) of MT-4129
Time frame: Up to Day 10
Plasma aldosterone
Time frame: Up to Day 10
Serum cortisol
Time frame: Up to Day 10
Plasma steroid hormones
Time frame: Up to Day 10
Urinary aldosterone
Time frame: Up to Day 10
Urinary cortisol
Time frame: Up to Day 10
Urinary sodium
Time frame: Up to Day 10
Urine potassium
Time frame: Up to Day 10
The record gives a start of Nov 2016, a primary completion of May 2017 and a completion of May 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lorundrostat hydrobromide
Mitsubishi Tanabe Pharma Corporation →